Twist Bioscience Corporation (NASDAQ:TWST) Receives $44.67 Consensus Target Price from Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $44.6667.

TWST has been the topic of several analyst reports. Evercore ISI reiterated an “outperform” rating and issued a $42.00 target price on shares of Twist Bioscience in a report on Monday, January 5th. Stephens assumed coverage on shares of Twist Bioscience in a research report on Monday, November 3rd. They set an “overweight” rating and a $41.00 price objective for the company. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Finally, Barclays increased their price target on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $34,774.72. Following the transaction, the senior vice president directly owned 142,187 shares of the company’s stock, valued at approximately $4,561,358.96. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the sale, the chief financial officer directly owned 137,031 shares of the company’s stock, valued at approximately $5,481,240. This trade represents a 2.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 66,437 shares of company stock valued at $2,136,365 over the last ninety days. Insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP bought a new position in shares of Twist Bioscience during the 3rd quarter worth about $28,000. Smartleaf Asset Management LLC raised its stake in Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares during the period. National Bank of Canada FI bought a new position in Twist Bioscience in the third quarter worth approximately $46,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after acquiring an additional 302 shares during the period. Finally, Geneos Wealth Management Inc. bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $97,000.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $42.94 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.64. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $55.33. The firm has a market cap of $2.63 billion, a PE ratio of -32.78 and a beta of 2.19. The firm’s fifty day moving average is $33.70 and its 200-day moving average is $31.46.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). The company had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million. Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. Sell-side analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.